Synergy between histone deacetylase inhibitors and DNA-damaging agents is mediated by histone deacetylase 2 in colorectal cancer

Previous studies have associated the overexpression of histone deacetylase 2 (HDAC2) and the presence of TP53 mutations with the progression to advanced stage drug resistant colorectal cancer (CRC). However, the mechanistic link between HDAC2 expression and the TP53 mutational status has remained un...

Descripción completa

Detalles Bibliográficos
Autores principales: Alzoubi, Samer, Brody, Leigh, Rahman, Sunniyat, Mahul-Mellier, Anne-Laure, Mercado, Nicolas, Ito, Kazuhiro, El-Bahrawy, Mona, Silver, Andrew, Boobis, Alan, Bell, Jimmy D., Hajji, Nabil
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2016
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5190114/
https://www.ncbi.nlm.nih.gov/pubmed/27283986
http://dx.doi.org/10.18632/oncotarget.9887

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5190114/
https://www.ncbi.nlm.nih.gov/pubmed/27283986
http://dx.doi.org/10.18632/oncotarget.9887

Ejemplares similares